Status:
COMPLETED
Study Evaluating IMA-638 in Healthy Japanese
Lead Sponsor:
Wyeth is now a wholly owned subsidiary of Pfizer
Conditions:
Healthy
Eligibility:
All Genders
20-45 years
Phase:
PHASE1
Brief Summary
The purpose of this study is to evaluate the safety and drug levels for single, ascending doses of IMA-638 in healthy Japanese subjects.
Eligibility Criteria
Inclusion
- Inclusion Criteria:
- First generation healthy Japanese men and women of non-childbearing potential.
Exclusion
Key Trial Info
Start Date :
June 1 2006
Trial Type :
INTERVENTIONAL
End Date :
July 1 2007
Estimated Enrollment :
Patients enrolled
Trial Details
Trial ID
NCT00340327
Start Date
June 1 2006
End Date
July 1 2007
Last Update
December 5 2007
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Glendale, California, United States, 91206